UNSPSC 51341805: Oseltamivir phosphate

This classification denotes an antiviral agent with the molecular formula C16H28N2O4.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4A3O49NGEZ, chemically known as 1-cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3r,4r,5s)- but more generally known as oseltamivir phosphate, which bears US NIH Compound Identifier 65028. European Medicines Agency schedules Oseltamivir phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12544MIG.

UNSPSC 51341805 Oseltamivir phosphate, a Commodity code, shows negligible recent state and local procurement activity aligned with its nominal scope. The four most recent opportunities tagged to this code—naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas HHS), medical and first aid supplies for fire rescue (City of Tampa), and generic pharmaceuticals through cooperative purchasing (Minnesota MMCAP)—do not involve oseltamivir or antiviral medications. The code appears to be misapplied across these solicitations, which span emergency medical supplies, pharmacy benefit program design, fire department consumables, and multi-source generic pharmaceutical distribution. No state or local issuing body has posted an opportunity specifically requesting oseltamivir phosphate or pharmaceutical agents within the antiviral class in the recent record.

The mismatch between the code's intended commodity and actual procurement activity suggests this code does not currently represent active buying patterns in state and local government. Firms pursuing state and local work in pharmaceutical supply chains should monitor the broader generic and OTC pharmaceutical family—particularly cooperative purchasing vehicles like MMCAP, which aggregates demand across multiple states and local jurisdictions—rather than track this specific commodity code. The cooperative purchasing model, as exemplified by the Minnesota MMCAP RFP (due March 26, 2026), represents the most active channel for state and local pharmaceutical procurement, with awards flowing through authorized wholesalers and pricing weighted heavily on competitiveness rather than set-asides or local preferences.